Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
38.00
+0.19 (0.50%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Company Description

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States.

The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.

Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.

It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy.

It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy.

Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Cytokinetics, Incorporated
Cytokinetics logo
Country United States
Founded 1997
IPO Date Apr 29, 2004
Industry Biotechnology
Sector Healthcare
Employees 498
CEO Robert Blum

Contact Details

Address:
350 Oyster Point Boulevard
South San Francisco, California 94080
United States
Phone 650 624 3000
Website cytokinetics.com

Stock Details

Ticker Symbol CYTK
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001061983
CUSIP Number 23282W605
ISIN Number US23282W6057
Employer ID 94-3291317
SIC Code 2834

Key Executives

Name Position
Robert I. Blum Chief Executive Officer, President and Director
Sung H. Lee Executive Vice President and Chief Financial Officer
Dr. Fady Ibraham Malik FACC, M.D., Ph.D. Executive Vice President of Research and Development
Andrew M. Callos Executive Vice President and Chief Commercial Officer
Dr. James A. Spudich Ph.D. Co-Founder and Member of Scientific Advisory Board
Jeff Lotz Vice President of Sales and Operations
Holly Laughlin Vice President of Accounting and Corporate Controller
Matt Yang Vice President of Corporate Finance and Financial Planning and Analysis
Steven M. Cook J.D. Senior Vice President of Global Supply Chain Operations and Technical Operations
Kari K. Loeser J.D. Vice President and Chief Compliance Officer

Latest SEC Filings

Date Type Title
Apr 21, 2025 144 Filing
Apr 15, 2025 144 Filing
Apr 10, 2025 ARS Filing
Apr 10, 2025 DEF 14A Other definitive proxy statements
Apr 8, 2025 144 Filing
Apr 7, 2025 144 Filing
Mar 31, 2025 PRE 14A Other preliminary proxy statements
Mar 14, 2025 144 Filing
Mar 13, 2025 144 Filing
Mar 10, 2025 8-K Current Report